Naslov
CYP2D6 Genotyping in Patients on Psychoactive Drug Therapy

Autori
Topić, Elizabeta ; Štefanović, Mario ; Ivanišević, Ana-Maria ; Blazinić, Franciska ; Čulav, Jadranka ; Skočilić, Željko.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Human genomics The basis of the medicine of tomorrow, Second Conference: Validating and Using Pharmacogenomics / Siest, Gerard - Basel : Roche diagnostics, 2000

Skup
Human Genomics, Second Joint Conference of IFCC-Roche Diagnostics: Validating and Using Pharmacogenomics

Mjesto i datum
Kyoto, Japan, 16.04.2000. - 19.04.2000

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
CYP2D6 polymorphisms; psychoactive drug therapy

Sažetak
The polymorphic isoenzyme CYP2D6 has a major role in the oxidative metabolism of a great deal of psychoactive drugs. Its six mutant alleles (null alleles *3, *4, *5, *6, *7 and *8) encode for inactive enzymatic molecules. A carrier of two mutant alleles is considered a poor metabolizer (PM) phenotype, while a carrier of only one damaged allele is considered an intermediate metabolizer (IM) phenotype. The aim of the study was to assess the prevalence of null alleles in a group of a group of psychiatric patients suffer from depression (n=48) and from schizophrenia (n=87) compared to the healthy individuals (n=145) by the method of multiplex allele specific PCR. Only CYP2D6*3,*4 and *5 mutant alleles were found among all examinees. Between depression and control group no significant difference was found for allele prevalence, genotype or phenotype distribution (p>0.05). But a significant difference was found for allele frequency (p=0.002), genotype (p=0.016), and phenotype frequency (p=0.018). The odds ratio of 2.542 for 2D6*4 and of 2.007 for 2D6*6 suggested a significant association of these alleles and schizophrenia state.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA